Kawasaki disease and cardiac involvement: an update on the state of the art

Area of Science:

• Pediatric Cardiology
• Rheumatology
• Immunology

Background:

• Kawasaki disease (KD) is an acute, self-limiting vasculitis of unknown cause.
• It is the primary cause of acquired heart disease in children aged 6 months to 5 years.
• KD can lead to coronary artery aneurysms, thrombotic occlusions, and sudden death, particularly in infants.

Purpose of the Study:

• To summarize the etiology, clinical presentation, and management of Kawasaki disease.
• To highlight the importance of timely intervention for preventing cardiac sequelae.
• To review current and emerging therapeutic strategies for KD.

Main Methods:

• Literature review of Kawasaki disease etiology, pathogenesis, and clinical manifestations.
• Analysis of treatment guidelines and outcomes for KD.
• Evaluation of recent advancements in KD pharmacotherapy.

Main Results:

• KD affects young children, causing inflammation of coronary arteries.
• Delayed treatment increases the risk of severe cardiac complications, including myocardial inflammation and impaired cardiac contractility.
• Intravenous immunoglobulin and aspirin are effective standard treatments.

Conclusions:

• Prompt initiation of therapy within 10 days of symptom onset is critical.
• While immunoglobulin and aspirin are effective, alternative treatments like corticosteroids and biologics are considered for refractory cases.
• Long-term cardiac monitoring may be necessary for affected children.